Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Hodgkin Disease 80Lymphoma 35Lymphoma, Large-Cell, Anaplastic 26Hematologic Diseases 21Recurrence 18Lymphoma, Non-Hodgkin 17Lymphoma, T-Cell, Peripheral 14Lymphoma, T-Cell, Cutaneous 13Lymphoma, T-Cell 13Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

Etoposide 2Drug Therapy 2tremelimumab 1trametinib 1pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1durvalumab 1dabrafenib 1cabozantinib 1cabazitaxel 1Paclitaxel 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Cyclophosphamide 1Cisplatin 1Carboplatin 1Brentuximab Vedotin 1BEP protocol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nonseminomatous germ cell tumor × Brentuximab Vedotin × Clear all
NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Indiana University

Phase 2 Terminated
18 enrolled 13 charts
Genitourinary

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡